Antisense oligonucleotides against Epstein-Barr virus

Details Antisense oligonucleotides against Epstein-Barr virus Antisense oligonucleotides against Epstein-Barr virus

1991-04-22

1993-09-07

Rollins, John W.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536245, 514934, A61K 4800, A61K 3170, C07H 2102

Patent

active

052429067

ABSTRACT:
Antisense oligonucleotides and pharmaceutical compositions containing same are provided for the inhibition of Epstein-Barr virus infections. These oligonucleotides are specifically hybridizable with RNA or DNA deriving from the EBNA-1 gene of the Epstein-Barr virus. One or more oligonucleotides are used in combination to hybridize to contiguous regions of the EBNA-1 mRNA immediately downstream of the translation initiation site.

REFERENCES:
patent: 5098890 (1992-03-01), Gewirtz et al.
Sample et al. Proc. Natl. Acad. Sci. 83: 5096-5100, 1986.
Pagano, J. S., "From Latency to Replication: Recent Studies of the Epstein Barr Virus", presented at the Fourth International Symposium on Epstein-Barr Virus and Associated Malignant Diseases, Sep. 23-28, 1990, Huallen, Taiwan, Republic of China.

Affiliated with

Also associated with

Rating

Antisense oligonucleotides against Epstein-Barr virus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense oligonucleotides against Epstein-Barr virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides against Epstein-Barr virus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-487882